Dexterio Competitors

Our mission is to detect cancer early, when it can be cured. We are working to change the trajectory of cancer mortality and bring stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care. We are a healthcare company, pioneering new technologies to advance early cancer detection. We have built a multi-disciplinary organization of scientists, engineers, and physicians and we are using the power of next-generation sequencing (NGS), population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine’s greatest challenges. GRAIL is headquartered in Menlo Park, California, with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. For more information, please visit grail.com. Community Guidelines: https://bit.ly/3xigb24

RadNet, Inc. is the largest U.S. provider of freestanding outpatient diagnostic imaging services, operating over 400 centers across key markets, including Arizona, California, Florida, and New York. In addition to imaging, RadNet offers AI-driven solutions under the DeepHealth brand, radiology IT, and teleradiology services. With over 10,000 employees and affiliated radiologists, RadNet is dedicated to advancing healthcare through innovation and expertise.

Heartflow is the global leader in AI-driven coronary artery disease (CAD) management, transforming how CAD — the world’s leading cause of death — is diagnosed and treated. Our advanced technology generates personalized, precision 3D heart models from a single CT scan, providing clinicians with the clarity and confidence to deliver earlier, more effective treatments — transforming CAD into a disease that can be managed for life. Heartflow One is the only complete, non-invasive, precision coronary care platform providing patient insights throughout the guideline-directed coronary CTA pathway. The AI-driven platform — including Roadmap™ Analysis, FFRct Analysis and Plaque Analysis — is supported by ACC/AHA guidelines and backed by more than 625 peer-reviewed publications. With over 650,000 patients treated, more than 1,800 leading institutions adopting our solution, and 99.5% of U.S. lives covered — Heartflow is redefining the standard of coronary care. We're a global company, with employees across the United States, Europe and Japan. Our headquarters are in San Francisco, California, with additional offices in California, Texas, the UK and Japan. We believe CAD shouldn’t be a silent threat. We’re changing the story of CAD by making it screenable, diagnosable, and manageable — empowering clinicians to save lives and giving patients more time for what matters most.